Simon C Ling1, Hsing-Hua S Lin2, Karen F Murray3, Philip Rosenthal4, Douglas Mogul5, Norberto Rodriguez-Baez6, Sarah Jane Schwarzenberg7, Jeffrey Teckman8, Kathleen B Schwarz5. 1. Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. Electronic address: simon.ling@sickkids.ca. 2. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA. 3. Department of Pediatrics, University of Washington, Seattle, WA. 4. Department of Pediatrics, UCSF, San Francisco, CA. 5. Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, MD. 6. Department of Pediatrics, UT Southwestern, Dallas, TX. 7. Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, MN. 8. Department of Pediatrics, Saint Louis University, Saint Louis, MO.
Abstract
OBJECTIVE: To determine the outcomes of chronic hepatitis B virus (HBV) infection in a large, prospectively studied cohort of children in the US and Canada. STUDY DESIGN: This was a prospective, observational study of children with chronic HBV enrolled in 7 clinical centers and evaluated at baseline, weeks 24 and 48, and annually thereafter, with analysis of demographic, clinical, physical examination, and blood test data. RESULTS: Among 362 children followed for a median of 4.2 years, elevated alanine aminotransferase (ALT) levels (>1 upper limit of normal) were present in 72% at last evaluation, including in 60% of children with loss of hepatitis B e antigen during follow-up and 70% of those who were hepatitis B e antigen negative at baseline. Significant ALT flares (male patients ≥400 U/L, female patients ≥350 U/L) occurred in 13 children. Of 129 children who fulfilled the American Association for the Study of Liver Diseases treatment criteria during follow-up, anti-HBV treatment was initiated in only 25. One child died (unrelated to liver disease), 1 developed cirrhosis, but no episodes of cirrhotic decompensation or hepatocellular carcinoma were observed. Decline in platelet count was inversely associated with ALT elevations. CONCLUSIONS: In a cohort of children with chronic HBV infection in the US and Canada, many children remained at risk of progressive liver disease due to active hepatitis, but major clinical outcomes such as cirrhosis, cancer, and death were rare. Many children who met criteria for treatment remained untreated.
OBJECTIVE: To determine the outcomes of chronic hepatitis B virus (HBV) infection in a large, prospectively studied cohort of children in the US and Canada. STUDY DESIGN: This was a prospective, observational study of children with chronic HBV enrolled in 7 clinical centers and evaluated at baseline, weeks 24 and 48, and annually thereafter, with analysis of demographic, clinical, physical examination, and blood test data. RESULTS: Among 362 children followed for a median of 4.2 years, elevated alanine aminotransferase (ALT) levels (>1 upper limit of normal) were present in 72% at last evaluation, including in 60% of children with loss of hepatitis B e antigen during follow-up and 70% of those who were hepatitis B e antigen negative at baseline. Significant ALT flares (male patients ≥400 U/L, female patients ≥350 U/L) occurred in 13 children. Of 129 children who fulfilled the American Association for the Study of Liver Diseases treatment criteria during follow-up, anti-HBV treatment was initiated in only 25. One child died (unrelated to liver disease), 1 developed cirrhosis, but no episodes of cirrhotic decompensation or hepatocellular carcinoma were observed. Decline in platelet count was inversely associated with ALT elevations. CONCLUSIONS: In a cohort of children with chronic HBV infection in the US and Canada, many children remained at risk of progressive liver disease due to active hepatitis, but major clinical outcomes such as cirrhosis, cancer, and death were rare. Many children who met criteria for treatment remained untreated.
Authors: Mayur Brahmania; Manuel Lombardero; Bettina E Hansen; Norah A Terrault; Anna S Lok; Robert P Perrillo; Steven H Belle; Adrian M Di Bisceglie; Jordan J Feld; William M Lee; Michael W Fried; Harry L A Janssen Journal: Clin Gastroenterol Hepatol Date: 2019-02-08 Impact factor: 11.382
Authors: Yusuke Shimakawa; Maud Lemoine; Harr Freeya Njai; Christian Bottomley; Gibril Ndow; Robert D Goldin; Abdoulie Jatta; Adam Jeng-Barry; Rita Wegmuller; Sophie E Moore; Ignatius Baldeh; Makie Taal; Umberto D'Alessandro; Hilton Whittle; Ramou Njie; Mark Thursz; Maimuna Mendy Journal: Gut Date: 2015-07-16 Impact factor: 23.059
Authors: Douglas B Mogul; Simon C Ling; Karen F Murray; Sarah J Schwarzenberg; Erin R Rudzinski; Kathleen B Schwarz Journal: J Pediatr Gastroenterol Nutr Date: 2018-10 Impact factor: 2.839
Authors: Jeffrey B Schwimmer; Winston Dunn; Gregory J Norman; Perrie E Pardee; Michael S Middleton; Nanda Kerkar; Claude B Sirlin Journal: Gastroenterology Date: 2010-01-11 Impact factor: 22.682